Regeneron Pharmaceuticals (REGN) seems to be facing escalating pressure on both sales and legal fronts. Nonetheless, numerous investment entities - including Private Advisor Group LLC, ING Groep NV, Fagan Associates Inc., and Truist Financial Corp - are increasingly their stock positions in the company. On a potentially discouraging note, Regeneron investors who have suffered monetary losses are being offered an opportunity to lead a securities fraud lawsuit. Notably, the FDA is in the process of evaluating a medication from Teva and Alvotech that may rival Regeneron's Eylea. With some shareholders having lost money on Regeneron, a class action lawsuit seems to be taking shape. However, other corporations like Hussman Strategic Advisors Inc., Callahan Advisors LLC and Kestra Investment Management LLC, are raising their stake in REGN notwithstanding. The drug cocktail that Regeneron developed, which was also administered to former President Trump, is under scrutiny for its effectiveness against COVID-19. Lastly, some Wall Street analysts predict that a certain undervalued stock has the potential to surge by 50% by 2025.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 05 Oct 2020 07:00:00 GMT to Sat, 22 Feb 2025 09:58:35 GMT - Rating 1 - Innovation -3 - Information 1 - Rumor -5
